Benitec Biopharma
BNTC
6 hedge funds and large institutions have $190K invested in Benitec Biopharma in 2017 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
245% more capital invested
Capital invested by funds: $55K → $190K (+$135K)
100% more funds holding
Funds holding: 3 → 6 (+3)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$56.6K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$53.8K |
| 3 |
Renaissance Technologies
New York
|
+$37.8K |
| 4 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
+$8.39K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WS
Wedbush Securities
Los Angeles,
California
|
-$39K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $61K | +$56.6K | +81 | New |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $58K | +$53.8K | +77 | New |
|
|
3
Renaissance Technologies
New York
| $41K | +$37.8K | +54 | New |
|
4
UBS Group
Zurich,
Switzerland
| $13K | – | – | – |
|
|
5
CIBC Private Wealth Group
Atlanta,
Georgia
| $9K | +$8.39K | +12 | New |
|
6
Bank of America
Charlotte,
North Carolina
| $8K | – | – | – |
|
|
WS
7
Wedbush Securities
Los Angeles,
California
| – | -$39K | -71 | Closed |
|
BNTC Hedge Fund Activity: Q4 2017 in Review
6 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q4 2017, worth a combined $190K — up 245% from $55K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new BNTC positions and 1 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Morgan Stanley, opening a new position worth an estimated $56.6K. The largest seller was Wedbush Securities, exiting entirely with an estimated $39K sold.
- 6 institutional investors held Benitec Biopharma (BNTC) as of Q4 2017, up from 3 in Q3 2017.
- Funds reported $190K of Benitec Biopharma stock for Q4 2017, up 245% quarter-over-quarter.
- 4 funds opened new Benitec Biopharma positions in Q4 2017 and 1 closed out, a net change of +3 holders.
- The largest Benitec Biopharma buyer in Q4 2017 was Morgan Stanley, an estimated $56.6K added.
- The largest Benitec Biopharma seller in Q4 2017 was Wedbush Securities, an estimated $39K sold.
Based on aggregated 13F filings for Q4 2017.